A phase II study of durvalumab (MEDI4736) plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma Herodotus - observacional - Institut d'Investigacions Biomèdiques August Pi i Sunyer

ID: GETNE T1812 DUTHY

Fecha inicio

26-05-2025

Fecha fin

N/A

Basté Rotllan, NeusInvestigador principal

Proyectos en Ámbito de Salud

Proyecto de Innovacion Sanitaria

A phase II study of durvalumab (MEDI4736) plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma Herodotus - observacional

Investigadores/as: Basté Rotllan, Neus

Hospital Clinic de Barcelona. Hospital Clinic de Barcelona - ICMHO (Sanitary institutions)